COVID-19 Update: Melior is operational

During this crisis Melior Discovery continues to operate as usual.  Our company has been deemed a critical business, exempt from operational restrictions imposed by the state of Pennsylvania.  We carry on with our research studies including those in pulmonary inflammation, pulmonary edema, and pulmonary fibrosis research. We are taking all necessary measures to ensure that we maintain a safe work environment.  This website will be promptly updated if our status changes.


Melior Discovery in vivo models that support COVID-19 research


The COVID-19 patients who react most severely to the SARS-CoV-2 virus develop an overly responsive immune signaling response, known as a cytokine storm, which is not seen in patients with non-severe symptoms. Although we know some of the risk factors associated with reacting to the virus in this way, it is not fully understood why some subjects have this reaction while others do not.

An outcome of the cytokine storm is pulmonary inflammation which in turn leads to pulmonary extravasation (edema; pneumonia).  Fluid laden pulmonary alveoli have poor oxygen exchange rates and are associated with reduced respiratory function. Patients experience lower oxygen saturation levels (SpO2) leading to Acute Respiratory Distress Syndrome (ARDS)  causing multiple organ failure and death.

Therefore, key components in this chain of events are pulmonary inflammation and pulmonary edema. For those patients who progress to ARDS but ultimately recover, some may still develop lasting pulmonary fibrosis.

Offering research scientists in their COVID-19 research studies, Melior routinely runs animal models that recapitulate aspects of a number of these key events.


Pulmonary Disease  Models

Get More Information on Melior’s models of pulmonary disease